Response to Sunitinib in Medullary Thyroid Cancer
Authors: Fergal C. Kelleher, Raymond McDermott
Journal: Annals of Internal Medicine (2008)

Letters1 April 2008Response to Sunitinib in Medullary Thyroid CancerFergal C. Kelleher, MB, MSc and Raymond McDermott, MD, PhDFergal C. Kelleher, MB, MScFrom Adelaide and Meath Hospital, Dublin 24, Ireland.Search for more papers by this author and Raymond McDermott, MD, PhDFrom Adelaide and Meath Hospital, Dublin 24, Ireland.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-148-7-200804010-00027 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: Medullary thyroid cancer (MTC) is the most aggressive form of well-differentiated thyroid cancer. Of all known cases, 80% are sporadic. Sporadic cases tend to present with advanced disease. In advanced disease, systemic chemotherapy is associated with low response rates of short duration. The rearranged in transformation (RET) proto-oncogene has a high frequency of aberrant expression in MTC, and trials of agents directed against this target are ongoing. In preclinical work, Kim and colleagues (1) have shown that sunitinib is a potent inhibitor of the RET/papillary thyroid cancer (PTC) kinase, and iatrogenic hypothyroidism is increasingly recognized in patients treated with ...References1. Kim DW, Jo YS, Jung HS, Chung HK, Song JH, Park KC, et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab. 2006;91:4070-6. [PMID: 16849418] CrossrefMedlineGoogle Scholar2. Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med. 2006;145:660-4. [PMID: 17088579] LinkGoogle Scholar3. Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2007;99:81-3. [PMID: 17202116] CrossrefMedlineGoogle Scholar4. Chatal JF, Campion L, Kraeber-Bodéré F, Bardet S, Vuillez JP, Charbonnel B, et al; French Endocrine Tumor Group. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol. 2006;24:1705-11. [PMID: 16549819] CrossrefMedlineGoogle Scholar5. Fagin JA. How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J Endocrinol. 2004;183:249-56. [PMID: 15531713] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Fergal C. Kelleher, MB, MSc; Raymond McDermott, MD, PhDAffiliations: From Adelaide and Meath Hospital, Dublin 24, Ireland.Acknowledgment: The authors thank P. Dwyer for assistance in the preparation of this manuscript.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoHypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors Jayesh Desai , Leila Yassa , Ellen Marqusee , Suzanne George , Mary C. Frates , Ming Hui Chen , Jeffrey A. Morgan , Samuel S. Dychter , P. Reed Larsen , George D. Demetri , and Erik K. Alexander Metrics Cited byThyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in OncologyMultiple endocrine neoplasia type 2: A reviewSunitinib for the treatment of thyroid cancerManagement of hereditary medullary thyroid carcinomaThe Structure of Clinical Translation: Efficiency, Information, and EthicsLes thérapies ciblées dans le cancer de la thyroïde : vers un traitement personnalisé ?Medical management of metastatic medullary thyroid cancerThree cases of sporadic medullary thyroid carcinoma in progression treated with sunitinibTres casos de carcinoma medular de tiroides esporádicos en progresión tratados con sunitinibTargeted Therapy of Thyroid CancerInhibition of the Ras/Raf/MEK/ERK and RET Kinase Pathways with the Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Medullary and Differentiated Thyroid MalignanciesHereditary and Sporadic Medullary Thyroid CarcinomaTargeted therapies for thyroid tumorsTargeted therapy of thyroid cancerNeoadjuvant Treatment of Unresectable Medullary Thyroid Cancer With SunitinibMolecular Targeted Therapies for Patients with Refractory Thyroid CancerPartial remission of metastatic papillary thyroid carcinoma with sunitinib. Report of a case and review of the literatureIn ReplyMultiple Endocrine NeoplasiaTyrosine kinase inhibitors and the thyroidA Case of Advanced Medullary Thyroid Carcinoma Successfully Treated with SunitinibMolecularly Targeted Therapies for Thyroid CancersTargeted Therapy for Endocrine Cancer: The Medullary Thyroid Carcinoma ParadigmThyroid Cancer in Young AdultsAdvances in Chemotherapy of Differentiated Epithelial and Medullary Thyroid CancersTargeting RET for thyroid cancer therapyReceptor tyrosine kinase inhibitors in thyroid cancer 1 April 2008Volume 148, Issue 7Page: 567KeywordsBiomarkersClinical trialsComputed axial tomographyDiarrheaHypothyroidismMedullary thyroid carcinomaMutationThyroidThyroid carcinomaThyroidectomy ePublished: 1 April 2008 Issue Published: 1 April 2008 Copyright & PermissionsCopyright © 2008 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...